Acta Labs is an independent product and commercialization lab turning promising technologies into products for public benefit across care delivery, diagnostics, and health security.
We translate promising technologies into products that address unmet needs in care delivery, diagnostics, and health security.
The current projects span frontline testing, sample preparation for pathogen surveillance, and diagnostic follow-up. Projects range from early concepts being scoped with potential partners to a software prototype.
Open, connected testing for routine respiratory care and emerging threats.
TriAct is a proposed low-cost reader and software platform designed to bring host-response testing, compatible rapid pathogen tests and decision support into frontline care. The first application being assessed is nasal host-response testing for respiratory illness.
Automated sample preparation for broad viral surveillance.
Beginning with municipal wastewater, ReadySeq aims to make sample preparation faster, simpler and less expensive by integrating processing and quality controls into a more consistent, automated workflow for downstream sequencing.
Follow-up management for high-risk diagnostic pathways.
ActOnDx helps care teams automate the follow-up chase after a positive high-risk diagnostic result: coordinating next steps, tracking follow-up over time, keeping patients informed, and documenting resolution so fewer patients fall through the cracks.
Acta Labs brings scientific, product development, and commercialization expertise to collaborations with healthcare teams, researchers, technology developers, and funders. We work together to define useful products, assess feasibility, and build a path from promising technologies to useful products.
Acta Labs undertakes selected advisory engagements with health technology companies and organizations. Work can include identifying promising applications, defining products, shaping positioning and evidence plans, and developing partnerships that support adoption.
We also welcome potential cofounders with complementary scientific, clinical, or technical expertise who want to help shape and build one of these concepts.
Development starts with what a product needs to enable, who will use it, and where it fits into their work. Our methods help translate those needs into product requirements, development plans, and evidence for adoption.
A structured method for assessing a health technology’s current stage, available evidence, remaining uncertainties, and the next decisions that evidence can support.
Start readiness checkA working canvas for mapping how a health technology could fit into real care settings, workflows, user needs, and adoption contexts.
Start translation canvasA tool for aligning product, clinical, operational, and commercial claims with the evidence available now.
Start claims map
Founder, Acta Labs
Anastasia builds products, partnerships, and new businesses around emerging health technologies. At GNA Biosolutions, she led product marketing and partnerships, and was a member of the product development and leadership teams that advanced a Point of Care molecular diagnostics platform from early development through emergency authorization and acquisition by HP Inc. She then helped establish HP Health Solutions, leading strategy, partnerships, and new-business creation across diagnostics, digital health, and pandemic preparedness. She now brings that experience to Acta Labs, focusing on products with a clear purpose and potential for public benefit.
Anastasia was an Entrepreneur in Residence at Ambitious Impact through its Founding to Give program, run in partnership with the School for Moral Ambition. She is currently developing her work in pandemic preparedness with support from Catalyze Impact.